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Available online xxxxSeveral lines of evidence implicate immunological/inﬂammatory factors in development of schizophrenia. Com-
plement is a key driver of inﬂammation, and complement dysregulation causes pathology inmany diseases. Here
we exploredwhether complement dysregulation occurred in ﬁrst episode psychosis (FEP) andwhether this pro-
vides a source of biomarkers. Eleven complement analytes (C1q, C3, C4, C5, factor B [FB], terminal complement
complex [TCC], factor H [FH], FH-related proteins [FHR125], Properdin, C1 inhibitor [C1inh], soluble complement
receptor 1 [CR1]) plus C-reactive protein (CRP) were measured in serum from 136 ﬁrst episode psychosis (FEP)
cases and 42 mentally healthy controls using established in-house or commercial ELISA. The relationship be-
tween caseness and variables (analytes measured, sex, age, ethnicity, tobacco/cannabis smoking) was tested
by multivariate logistic regression.
Whenmeasured individually, only TCCwas signiﬁcantly different between FEP and controls (p=0.01). Stepwise
selection demonstrated interdependence between some variables and revealed other variables that signiﬁcantly
and independently contributed to distinguishing cases and controls. Theﬁnalmodel includeddemographics (sex,
ethnicity, age, tobacco smoking) and a subset of analytes (C3, C4, C5, TCC, C1inh, FHR125, CR1). A receiver oper-
ating curve analysis combining these variables yielded an areaunder the curve of 0.79 for differentiating FEP from
controls. This model was conﬁrmed by multiple replications using randomly selected sample subsets.
The data suggest that complement dysregulation occurs in FEP, supporting an underlying immune/inﬂammatory
component to the disorder. Classiﬁcation of FEP cases according to biological variables rather than symptoms
would help stratify cases to identify those that might most beneﬁt from therapeutic modiﬁcation of the inﬂam-
matory response.
© 2017 Published by Elsevier B.V.Keywords:
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Predictors1. Introduction
First episode psychosis (FEP) refers to patients who have presented
with and received treatment for their ﬁrst psychotic episode (Weiden et
al., 2007), which may be the ﬁrst presentation of disorders such
as schizophrenia, schizoaffective disorder or bipolar disorder. The
aetiology and pathogenesis of psychosis is not yet fully understood,
although the weight of evidence suggests a contribution from both
genetic and environmental factors (Tsuang et al., 2004; Brown, 2011).
In the absence of a biological marker, current diagnosis relies upon clin-
ical assessment, and treatment is largely empirical (Li et al., 2012). It is
therefore not surprising that treatment response rates are unsatisfacto-
ry; multiple treatment failures are common and relapse is frequentg, School of Medicine, Cardiff
).
l., Complement systembioma(Emsley et al., 2013). The lack of biomarkers also contributes to difﬁcul-
ties in early diagnosis, disease stratiﬁcation, therapeutic choice and pre-
diction of outcome (Weickert et al., 2013). A handful of plasma and
serum biomarkers have been described but have often failed to repli-
cate, have not gainedwidespread acceptance andhave not provided sig-
niﬁcant insight into pathogenesis or optimal therapeutic strategy
(Weickert et al., 2013). The goal of the current study was to investigate
the potential for using complement-related proteins as serum bio-
markers with prognostic and/or theranostic value.
A potential link between inﬂammation and both FEP and schizo-
phrenia has been proposed for decades (Ganguli et al., 1987; Kirch,
1993; Goldsmith et al., 2016); however, the usefulness of inﬂammatory
or immunological markers is yet to be established. Several lines of evi-
dence, particularly in schizophrenia, suggest that immunological factors
contribute to the development of psychosis (van Kesteren et al., 2017).
Maternal virus infection has been proposed as a risk factor for schizo-
phrenia and bipolar disorder (Schmitt et al., 2014; Parboosing et al.,
2013), and inﬂammatory cytokines such as interleukin (IL)-1, IL-6rkers in ﬁrst episodepsychosis, Schizophr. Res. (2017), https://doi.org/
Table 1
The demographics and lifestyle variables of the study population. χ2; chi-square test, W;
Mann-Whitney test. Variables signiﬁcant at p = 0.05 are in bold and underlined.
Variable Controls n
(%)
Cases n (%) Test
statistic
p-Value
Numbers 42 (100%) 136 (100%)
Age in years, mean (SD) 37.55 (14.44) 32.51 (10.12) W= 3343.5 0.09
Sex, male 19 (45.24%) 96 (71.11%) χ2 = 7.94 0.005
Tobacco smoking 12 (28.57%) 100 (73.53%) χ2 = 15.33 0.001
Cannabis smoking 14 (33.33%) 94 (69.12%) χ2 = 4.11 0.04
Tobacco and cannabis
smoking
9 (21.43%) 83 (61.03%) χ2 = 10.29 0.001
Ethnicity
White British 20 (47.62%) 38 (27.94%) χ2 = 4.80 0.03
Mixed 3 (7.14%) 5 (3.68%) χ2 = 0.27 0.60
White other 5 (11.90%) 17 (12.50%) χ2 = 0 1
Various Asian 4 (9.52%) 8 (5.88%) χ2 = 0.22 0.64
Black Caribbean 3 (7.14%) 26 (19.12%) χ2 = 2.55 0.11
Black African 3 (7.14%) 28 (20.59%) χ2 = 3.15 0.08
No information 4 (9.52%) 14 (10.29%) χ2 = 0 1
2 M. Kopczynska et al. / Schizophrenia Research xxx (2017) xxx–xxx(Drzyzga et al., 2006) and transforming growth factor (TGF)-α (Kim et
al., 2009), which drive inﬂammation and act as modulators of immune
response, are increased in plasma in some schizophrenia patients
(Watanabe et al., 2010). Importantly, treatmentwith anti-inﬂammatory
medication is associated in some studies with reduction of core symp-
toms of schizophrenia (Drzyzga et al., 2006). The data on immunologi-
cal/inﬂammatory factors is, however, inconsistent, suggesting that a
targeted approach focusing on speciﬁc inﬂammatory pathways might
be more rewarding.
The complement system is a major effector of innate immunity and
an adjuvant of adaptive immunity. Complement comprises around 30
plasma and cell-surface proteins that interact with one another to
induce a series of inﬂammatory responses involved in defence against
infection (Ricklin et al., 2010). Complement is activated via three initiat-
ing pathways (classical, alternative and lectin), all of which converge on
a common effector pathway with formation of the membrane attack
complex (MAC). Complement acts through production of: 1. opsonins
(C3b, iC3b) increasing the ability of macrophages and neutrophils to
phagocytose; 2. anaphylatoxins (C3a, C5a) inducing local and systemic
inﬂammatory responses, increasing the permeability of blood vessels
and attracting neutrophils; 3. through direct killing of organisms by for-
mation of the MAC which disrupts the phospholipid bilayer of a target
cell (Ingram et al., 2012). Complement system function is regulated
(accelerated or inhibited) by complement regulatory proteins present
in ﬂuid-phase or membrane-bound (Noris and Remuzzi, 2013).
Dysregulation of the complement system in schizophrenia has been
noted in a few small studies, notably increased activation of the classical
complement pathway (Mayilyan et al., 2008; Hakobyan et al., 2005),
and decreased complement hemolytic activity, indicative of consump-
tion (Mayilyan et al., 2008). However, data regarding complement
changes are inconsistent, with one study reporting increased plasma
levels of C3 and C4 (Mayilyan et al., 2008), while another described de-
creased levels of these proteins (Wong et al., 1996). This lack of consen-
sus, together with a growing evidence base indicating that complement
is involved in brain development (Stephan et al., 2012; Stevens et al.,
2007), aswell as the recent genetic study implicatingC4 as a susceptibil-
ity locus for schizophrenia (Sekar et al., 2016), has motivated us to ex-
plore whether changes in the complement system can be detected in
FEP in comparison with healthy controls. Here we describe the mea-
surement in serum from FEP cases and healthy controls of a selected
panel of complement proteins and activation products with the aim of
gaining insight into underlying pathology and identifying candidate
biomarkers. The marker set was chosen to interrogate classical (C1q,
iC3b, C3, C4), alternative (Properdin, FB, FH, iC3b) and terminal (TCC)
activation pathways. Selected markers have been implicated in patho-
physiology of mood disorders such as schizophrenia (Hakobyan et al.,
2005; Mayilyan et al., 2008) and bipolar affective disorders (Akcan et
al., 2017), and/or neurological and neurodegenerative disorders
such as Alzheimer's disease (Kolev et al., 2009), Parkinson's disease
(Loefﬂer et al., 2006),multiple sclerosis (Ingram et al., 2012) and epilep-
sy (Aronica et al., 2007; Jamali et al., 2010). CPR was measured because
of its widely accepted use as a benchmark of inﬂammatory state.
2. Methods
2.1. Samples
In the present study, 136 FEP patients and 42 mentally healthy con-
trols were recruited as part of the Physical health and substance Use
Measures in Psychosis (PUMP) and the Genetics and Psychosis (GAP)
studies. The demographics of all study participants is presented in
Table 1. All patients aged 18–65 years who presented with FEP were
approached. The age of onset of psychosis was within 6 months of pre-
sentation. Patients met the ICD-10 criteria for psychosis (codes F20–29
and F30–33) and were recruited from mental health Trusts in London
and South-East England. Patients were interviewed using the SchedulesPlease cite this article as: Kopczynska,M., et al., Complement systembioma
10.1016/j.schres.2017.12.012for Clinical assessment in Neuropsychiatry (SCAN) present state exam-
ination protocol and ICD-10 diagnoses were derived from the Opera-
tional Criteria (OPCRIT) algorithm (Rucker et al., 2011). If patients
were too unwell to cooperate, they were re-contacted after the start of
treatment. The majority of the patients were not drug naïve at the
time of blood sample collection; details of drug therapy were not avail-
able for the majority. Volunteer controls, recruited using internet and
newspaper advertisements and by distributing leaﬂets at train stations,
shops, and job centres, were administered the Psychosis Screening
Questionnaire (Bebbington and Nayani, 1995) and were excluded if
they met the criteria for a psychotic disorder or if they reported a previ-
ous diagnosis of psychotic illness. Ethnicitywas self-reported. Someeth-
nicity groups were merged to provide bigger populations for statistical
analysis. The two smallest groups remaining (Mixed and Asian) could
not easily bemergedwith another ethnicity group. The original number
of controls was low compared to the cases and was further reduced by
removing from analysis samples of mothers of cases previously used
as controls in the GAP study. All cases and controls included in the
study gave written informed consent. Ethical approval was granted by
the Research Ethics Committee of The Joint South London andMaudsley
and The Institute of Psychiatry NHS Research Ethics Committee.
2.2. Immunoassays
The concentrations of 11 complement analytes: C1q, C3, C4, C5, Fac-
tor B (FB), Factor H (FH), FH-related proteins 1, 2 and 5 (FHR125), Pro-
perdin, C1 inhibitor (C1inh), soluble complement receptor 1 (sCR1),
and terminal complement complex (TCC) were measured using
established in-house enzyme-linked immunosorbent assays (ELISA)
(Table 2). C-reactive protein (CRP) was measured using a commercial
ELISA (CRP Duoset DY1707; R&D Systems, Abingdon, UK). The samples
available for analysis comprised serum aliquots (0.2–0.5 ml) that had
been stored at−80 °C and not subjected to freeze-thaw. For in-house
ELISA, Maxisorp (Nunc, Loughborough, UK) plates were coated with af-
ﬁnity-puriﬁed capture antibody overnight at 4 °C, and blocked (1 h at
room temperature (RT)) with either 3% non-fat dried milk (NFM) or
1% bovine serum albumin (BSA) in phosphate-buffered saline contain-
ing 0.1% Tween 20 (Sigma Aldrich) (PBS-T). After washing wells in
PBS-T, puriﬁed protein standards or serum samples optimally diluted
in 1% NFM or 0.1% BSA in PBS-T, were added in duplicate and incubated
for 1.5 h at 37 °C. Different sample dilutions were used for different as-
says (Table 2). Wells were washed 3× with PBS-T then incubated (1 h)
at RT with detection antibody (unlabelled or labelled with horseradish
peroxidase (HRP)) and washed 3× with PBS-T. For assays using
unlabelled detection antibodies, HRP labelled secondary antibody
(anti-mouse or anti-rabbit IgG as appropriate) was added to wells,rkers in ﬁrst episodepsychosis, Schizophr. Res. (2017), https://doi.org/
Table 2
The table lists the antibodypairs used in themultiplex sets, the sources of the antibodies and the standards, dilutions and assayworking range.MM;mousemonoclonal antibody, RP; rabbit
polyclonal antibody, HRP; horseradish peroxidase (antibodies labelled in-house), TCC; terminal complement complex; C1Inh; C1 inhibitor; FB; Factor B; FH; Factor H; FHR125; Factor H
related proteins 1, 2, and 5; CR1; complement receptor 1; CRP; C-reactive protein. A kind gift from SRdC – Prof S. Rodriguez de Cordoba, Madrid. ECACC: European Collection of Authen-
ticated Cell Cultures, Hycult: http://www.hycultbiotech.com/; CompTech: http://www.complementtech.com/; R&D Systems: http://www.rndsystems.com/.
Assay Capture antibody Detection antibody Standard Working range
(ng/ml)
Sample
dilution
C1q MM anti-C1q mAb (WL02, Hycult) MM anti-C1q (DJ01, Hycult)-HRP C1q (in-house puriﬁed) 32–1000 1:1000
C3 RP anti human C3 (in-house) RP anti-C3 (in-house)-HRP C3 (CompTech) 32–1000 1:16,000
C4 RP anti-C4 (in-house) RP anti-C4 (in-house)-HRP C4 (CompTech) 8–500 1:4000
C5 RP anti-C5 (in-house) MM anti-C5 (2D5; in-house)-HRP C5 (in-house puriﬁed) 32–1000 1:200
Factor B MM anti-FB (JC1; in house) MM anti-FB (MBI-5; in-house)-HRP FB (in-house puriﬁed) 64–1000 1:500
Factor H MM anti-FH (OX24; ECACC) MM anti-FH (35H9; in-house)-HRP FH (in-house puriﬁed) 16–1000 1:3000
C1inh MM anti-C1inh (in-house) RP anti-C1inh (in-house)-HRP C1 inhibitor (Cinryze drug) 4–100 1:16,000
Properdin MM anti-properdin (1.1.1; Gift of SRdC) MM anti-properdin (12-14-2; gift of SRdC)-HRP Properdin (CompTech) 7–100 1:400
FHR125 MM anti-FHR125 (MBI125; in-house) RP anti-FH (in-house)-HRP FHR125 (in-house) 4–250 1:4000
TCC MM anti-TCC (aE11, Hycult) MM anti C8 (E2, in-house)-HRP TCC (in-house puriﬁed) 60–1000 1:50
CR1 RP anti-CR1 (in-house) MM anti-CR1 (MBI35; in-house)-HRP CR1 (in-house puriﬁed) 16–500 1:2
CRP MM anti-CRP (R&D systems; DuoSet) MM anti-CRP-biotin/avidin-HRP (R&D systems; DuoSet) CRP (R&D systems; DuoSet) 0.8–50 1:200
Table 3
Complement analyte differences between ﬁrst episode psychosis (FEP) and controls.
Signiﬁcance of differences was tested using the Mann-Whitney test. Variables signiﬁcant
at p = 0.05 are in bold and underlined. TCC; terminal complement complex; C1inh; C1
inhibitor; FB; Factor B; FH; Factor H; FHR125; Factor H related proteins 1, 2, and 5; CR1;
complement receptor 1; CRP; C-reactive protein.
Assay FEP Control p Value
Mean (μg/ml) StDev Mean StDev
C1q 128.31 28.53 134.70 27.34 0.07
C3 1698.74 1973.34 1871.69 2119.61 0.46
C4 475.39 129.39 463.42 143.23 0.70
C5 81.37 38.60 91.56 45.23 0.30
FB 102.46 35.62 107.20 40.93 0.72
FH 383.18 185.39 357.89 136.71 0.76
C1inh 101.63 31.12 105.68 39.66 0.88
Properdin 4.34 2.85 4.46 2.69 0.76
FHR125 9.69 6.33 10.67 5.42 0.31
TCC 30.29 14.54 36.22 12.85 0.01
CR1 0.02 0.01 0.02 0.01 0.52
CRP 4.78 5.65 3.76 3.40 0.72
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Phenylenediamine dihydrochloride (OPD, SIGMAFAST™, Sigma-Al-
drich) and absorbance (492 nm)wasmeasured. Standardswere includ-
ed on each plate and samples from controls and cases were randomly
assigned to eliminate assay bias. A nonlinear regression model was
used to ﬁt standard curves generated by ELISA. Total protein concentra-
tion (μg/ml) was automatically calculated by reference to the standard
curve using GraphPad Prism. Detection limits, working ranges and
assay performance were determined as described (Ingram et al.,
2012), using serum from 62 local healthy controls.
2.3. Statistical methods
Univariate statistical tests were performed using theMann-Whitney
U test for comparison between the cases and controls, for each analyte.
Univariate associations between the condition and categorical variables
such as sex or ethnicitywere tested using the Chi-square test. In order to
avoid loss of information andmaximise the power of the study, we used
all the samples and variables that were available. Stepwise logistic re-
gression models were tested, including the measured analytes together
with co-variates such as sex, age, ethnicity and the consumption of to-
bacco and cannabis to adjust for their impact on measured analytes in
the cohort. Due to the relatively small number of samples available,
we chose to perform stepwise selection on the complete available
dataset. The selectedmodels were then tested using Receiver Operating
Curve (ROC) analyses, with leave-one-out cross-validation. In order to
rule out the possibility of over-ﬁtting of the model using this approach,
we performed replications of stepwise models on different subsets of
the data. The most stable variables - those most often selected and
most signiﬁcant - were identiﬁed. For each replicate, an AUC was com-
puted and the distribution of AUCs across the replicates measured. All
tests and analyses were performed with the statistical software R, in-
cluding the pROC packages.
3. Results
3.1. Serum levels of TCC and demographic variables distinguish FEP from
control
Of twelve analytesmeasured, only one, TCC, was signiﬁcantly differ-
ent between FEP and control populations (controls, 36.22 μg/ml; FEP
30.29 μg/ml: p = 0.01 Table 3). C1q levels were lower in FEP patient
serum compared to controls at a trend level (controls, 134.70 μg/ml;
FEP, 128.31 μg/ml: p = 0.07). Application of the Bonferroni correction
resulted in a p-value for TCC of 0.12, indicating only a trend but not sig-
niﬁcance; however, this is a very conservative test, particularly in the
presence of many dependent variables, because the Bonferroni testPlease cite this article as: Kopczynska,M., et al., Complement systembioma
10.1016/j.schres.2017.12.012assumes the multiple tests to be independent. A robust, and computa-
tionally more intensive, alternative to the Bonferroni correction is the
permutation correction (Sham and Purcell, 2014); this correction gave
an adjusted p-value for TCC of 0.014. The association of FEP with sex,
ethnicity, tobacco and cannabis consumption was assessed using Chi-
square tests; all four of these categorical variables showed signiﬁcant
or near-signiﬁcant effect (sex, p b 0.005; ethnicity, p b 0.07; tobacco, p
b 0.00005; cannabis, p b 0.04). These differences in sex, ethnicity, tobac-
co and cannabismayhave arisen, at least in part, as a consequence of the
ascertainment protocols; we include them in the models below to ad-
just for any potential impacts onmeasured analytes. Of note, themajor-
ity of the patients were not drug naïve at the time of blood sample
collection and details of drug therapy were not available; however,
one of us recently reviewed the impact of psychotropic drugs on inﬂam-
mation/immunity and found no consistency for reported effects in the
literature (Baumeister et al., 2016).
3.2. Logistic regression and development of prediction models
To ﬁnd the set of analytes and demographics that best distinguished
FEP and controls, different combinationswere tested inmultiple logistic
regressionmodels. We ﬁtted a logistic regression to establish predictive
values of complement risk factors. We then performed a stepwise pro-
cedure, to only include in the model the signiﬁcant variables (details
of the analyte selection are shown in Supplementary Table 1). The
ﬁrst multivariate model (Model A) was tested on the whole study pop-
ulation (178 samples: 136 FEP; 42 controls). Because data on smokingrkers in ﬁrst episodepsychosis, Schizophr. Res. (2017), https://doi.org/
4 M. Kopczynska et al. / Schizophrenia Research xxx (2017) xxx–xxxstatus was not available for a signiﬁcant proportion (34/178) of the
sample, this variable was omitted from the Model A. The resulting
model after stepwise selection comprised sex, age, ethnicity, TCC and
CRP (Table 4A). People of black Caribbean and black African ethnicities
were signiﬁcantly over-represented in the cases in comparison to con-
trol populations.With this selectedmodel, a leave-one-out cross-valida-
tion was performed on the dataset to estimate its accuracy. At each
iteration, one sample was removed, the model was trained on the re-
maining samples, coefﬁcients were estimated, enabling the evaluation
of the probability of caseness for the sample that had been removed.
Predictions were then compared to the actual outcomes, resulting in
an AUC of 0.72 (Fig. 1A). Sensitivity and speciﬁcity in the model depend
on the prediction probability thresholdwhich classiﬁes the samples into
two groups, “predicted cases” and “predicted controls”. The lower the
threshold, the more cases are predicted and the more likely the actual
cases are correctly predicted, thus sensitivity increases, and vice versa.
The optimal threshold was obtained by minimising the difference be-
tween sensitivity and speciﬁcity; the values of sensitivity and speciﬁcity
were respectively 0.79 and 0.64, with a minimised difference probabil-
ity threshold (MDT) of 0.72.
According tomultiple studies, tobacco and cannabis smoking are in-
timately associated with schizophrenia and could have implications for
the underlying neurobiology of this illness (Kelly and McCreadie, 2000;
de Leon et al., 2002; Andréasson et al., 1987; Moore et al., 2007). In our
study, history of tobacco and cannabis smoking are both signiﬁcantly
over-represented in FEP patients in comparison to controls. Therefore,
a second model (Model B) was tested to adjust for the smoking vari-
ables;missing data reduced the number of samples to n=144. This sec-
ond stepwise selection for theModel B comprised sex, ethnicity, tobacco
smoking, and the complement analytes C3, C4, C5, TCC, C1inh, FHR125,
CR1 (Table 4B). The most signiﬁcant (p b 0.05) variables were sex,Table 4
Stepwise selection of the logistic regression analysis including the demographics, (A) First
model –Model A, tested on thewhole study populationwithout tobacco variable; (B) Sec-
ondmodel –Model B tested on the study population with tobacco variable available. Var-
iables signiﬁcant at p=0.05 are inbold andunderlined. Ethnicity:White Britishwas taken
as a reference group. TCC – terminal complement complex; C1inh – C1 inhibitor; FB – Fac-
tor B; FH – Factor H; FHR125 – Factor H related proteins 1, 2, and 5; CR1 – complement
receptor 1; CRP – C-reactive protein; OR – odds ratio; CI – conﬁdence interval.
Variables p-Value logOR (95% CI)
A
Sex (male) 0.051 0.81 (−0.004; 1.62)
Age 0.01 −0.04 (−0.08;−0.01)
Ethnicity: white British n/a n/a
Ethnicity: mixed 0.46 −0.63 (−2.31; 1.05)
Ethnicity: white other 0.15 0.92 (−0.34; 2.17)
Ethnicity: various Asian 0.64 0.36 (−1.14; 1.86)
Ethnicity: black Caribbean 0.01 1.81 (0.38; 3.24)
Ethnicity: black African 0.004 2.40 (0.76; 4.03)
Ethnicity: no information 0.24 0.84 (−0.55; 2.23)
TCC 0.001 −0.05 (−0.08;−0.02)
CRP 0.19 0.06 (−0.03; 0.15)
B
Sex (male) 0.001 2.55 (1.07; 4.03)
Ethnicity: white British n/a
Ethnicity: mixed 0.33 −1.35 (−4.05; 1.35)
Ethnicity: white other 0.97 −0.03 (−1.90; 1.84)
Ethnicity: various Asian 0.13 1.97 (−0.57; 4.50)
Ethnicity: black Caribbean 0.02 2.98 (0.43; 5.53)
Ethnicity: black African 0.01 2.92 (0.78; 5.07)
Ethnicity: no information 0.11 1.98 (−0.44; 4.40)
Tobacco 0.0003 2.81 (1.30; 4.33)
CR1 0.16 −86.98 (−207.87; 33.93)
TCC 0.098 −0.04 (−0.09; 0.01)
C3 0.02 −0.0003 (−0.0005;−0.00005)
C4 0.01 −0.009 (−0.01;−0.0024)
C5 0.09 −0.01 (−0.03; 0.002)
C1inh 0.08 −0.02(−0.03; 0.002)
FHR125 0.08 0.12 (−0.02; 0.26)
Please cite this article as: Kopczynska,M., et al., Complement systembioma
10.1016/j.schres.2017.12.012ethnicity, tobacco smoking, and the complement analytes C3 and C4.
Male sex was over-represented in FEP cases in comparison to controls.
Four additional complement biomarkers, C5, TCC, C1inh and FHR125,
were signiﬁcant at the 0.1 level and were included in the model. Of
note, the age variable was not statistically signiﬁcant (p = 0.55) in
Model B. There was a weak but signiﬁcant association between the
age and the smoking status (p = 0.097) that mirrored the association
between age and FEP status (young age associates with smoking associ-
ates with caseness). Because of the association with smoking status, in-
cluded in Model B, the age variable no longer provided additional
signiﬁcance and was therefore omitted in Model B. We also observed
weak but signiﬁcant correlations between age and some of the comple-
ment factors included inModel B: C4 (Spearman correlation (sc) 0.21; p
=0.01), C5 (sc 0.16; p=0.05) and FHR125 (sc 0.16; p=0.05). CRPwas
not included in Model B; due to its correlation with tobacco smoking, it
added no further value in themultivariateModel B. Cannabis consump-
tion was not included in Model B; because of its strong association with
tobacco smoking (p b 0.0001), adding this variable did not improve the
model. Themodelwas testedwith leave-one-out cross-validation as de-
scribed above; the ﬁnal predictive value (AUC) was 0.79 (Fig. 1B). This
second model has respective sensitivity and speciﬁcity of 0.85 and
0.69, with MDT = 0.78.
3.3. Analysis of correlations between variables and inﬂuence of potential
confounding factors
Signiﬁcant correlations between the complement analytes were
identiﬁed; however, for most pairs the correlationswereweak (Supple-
mentary Fig. 1). These correlations were not considered in the ﬁnal
Models because their inclusion in tests did not improve the predictive
performance; further, inclusion carries the risk of overﬁtting of the
models.
We also investigated the inﬂuence of demographic and lifestyle var-
iables on complement protein levels. Tobacco smoking was associated
with increased levels of FH (p = 0.046) and reduced TCC (p = 0.008)
(Supplementary Table 2). Cannabis consumption was associated with
a signiﬁcant reduction in C5 levels (p = 0.001) and trending reduction
in C4 (p = 0.086), C1q (p = 0.051) and CR1 (p = 0.081) (Supplemen-
tary Table 3). Male sex was associated with lower TCC levels (p= 0.03)
and higher C4 levels (p = 0.04) (Supplementary Table 4). In previous
studies, a nonlinear association with age has been described for C3
and C4, which also differs in women and men (Ritchie et al., 2004);
we found a positive association between age and C4 in women (p =
0.02), but not in men (p = 0.71) but no association between age and
C3 in either sex.
3.4. Further analysis for incorrectly classiﬁed cases
We explored whether there were any speciﬁc differences between
the correctly and incorrectly classiﬁed individuals in Model B. We iden-
tiﬁed 25 misclassiﬁed samples, 17 false negatives and 8 false positives
from the 144 samples tested. Of these, 19 were female (13 false nega-
tives, 6 false positives); Chi square testing gave p = 9.1e-6 for female
sex as a factor in miss-classiﬁcation. For tobacco consumption, 11 of
the miss-classiﬁed samples were from non-smokers and 14 from
smokers; Chi square testing gave p = 0.009 for smoking as a factor in
miss-classiﬁcation.
3.5. Sensitivity analysis
Black Caribbean and Black African ethnicities were much more fre-
quent in cases compared to controls. To test the impact of this on the
model, a stepwise model was ﬁtted after removing these samples
fromboth case and control sets. The resultingmodel comprised sex, eth-
nicity, tobacco consumption, C3, C4, C5, TCC and CRP. The predictive
power of this model was comparable to that of Model B using therkers in ﬁrst episodepsychosis, Schizophr. Res. (2017), https://doi.org/
Fig. 1. Receiver operated characteristic (ROC) curves to predict the probability of FEP compared to control subjects. The ﬁrst model (A) comprised demographics (sex, age, ethnicity) and
contributing analytes TCC and CRP; this gave an AUC statistic of 0.72. The values of sensitivity and speciﬁcity were respectively 0.79 and 0.64, with a minimised difference probability
threshold (MDT) of 0.72.The second model (B) included tobacco smoking status as an additional demographic factor and contributing analytes comprised C3, C4, C5, TCC, C1inh,
FHR125, CR1; this gave an AUC statistic of 0.79. This model has respective sensitivity and speciﬁcity of 0.85 and 0.69, with MDT = 0.78.
5M. Kopczynska et al. / Schizophrenia Research xxx (2017) xxx–xxxcomplete sample sets (AUC of 0.80). We also tested the impact of re-
moving samples with CRP values above 10 μg/mL, because these
might represent participants with acute infection. The resulting
model, comprising sex, ethnicity, tobacco consumption, C3, C4, C5,
TCC gave the same predictive power (AUC of 0.80).
3.6. Replication
In order to rule out the possibility of over-ﬁtting of the model using
this approach, we performed 100 replicates of stepwise models on
different subsets of the data (containing all available analytes as demo-
graphics). For each replicate, the datasetwas randomly split into a train-
ing set (80%) on which we performed a stepwise methodology, before
testing the selected model on the remaining validation set (20%) and
computing the corresponding AUC. The variables most strongly associ-
atedwith FEPwere sex, tobacco consumption and ethnicity, selected re-
spectively 100, 96 and 79 times, and signiﬁcant (p b 0.05) 92, 85 and 66
times (all out of 100 replications). After controlling for these co-variates,
the most stable biomarkers were C4 and C3, included in the model 92
and 80 times, and signiﬁcant (p b 0.05) 75 and 57 times. CR1, C5 and
TCC were selected in the model N50% of the time. These most stable
co-variates and biomarkers were identical to those selected when
performing stepwise regression on the whole dataset. The median
AUC from these 100 replicates was 0.69 (standard deviation of 0.13).
The decreased AUC compared to whole dataset analysis (0.79) can be
explained by the smaller size of the training sets (115 versus 143).
4. Discussion
There has been debate over the past few years about the criteria
currently used to classify patients with psychiatric disorders. The lack
of objective and quantitative diagnostic criteria means that we rely on
symptom-based categorisation when deciding on patient classiﬁcation
and management. A classiﬁcation of patients according to underlying
biology rather than symptoms would simplify the path towards effec-
tive and patient-appropriate treatments (Mondelli et al., 2015).Please cite this article as: Kopczynska,M., et al., Complement systembioma
10.1016/j.schres.2017.12.012Accumulating evidence has implicated inﬂammation and the immune
system in the aetiology of psychosis (Najjar and Pearlman, 2015;
Kodavali et al., 2014), suggesting that biological markers might emerge
from a better understanding of these systems in psychiatry; comple-
ment is one such system (Hakobyan et al., 2005).
Complement has recently emerged as a key player in brain develop-
ment; C1q and downstream classical pathway activation productsmark
synapses for elimination during post-natal brain remodelling, a process
that is essential for brain development, maturation, and optimal
function (Stevens et al., 2007). This physiological process has also
been implicated in pathological synapse elimination in the context of
schizophrenia and dementia (Stevens et al., 2007; Stephan et al.,
2012; Hong et al., 2016; Kodavali et al., 2014; Prasad et al., 2016). The
demonstration that functional allelic variation at the C4 gene explains
much of the well-known genetic association between the MHC locus
and schizophrenia further supports a role in thedisorder for the classical
pathway of complement (Sekar et al., 2016). Taken together, these data
support a scenario where dysregulated activation of the complement
classical pathway is, at least in part, responsible for the reduced synapse
number that typiﬁes the brain in schizophrenia.Much remains to bedis-
covered, notably when during disease development these events occur,
and therefore identifying complement system changes in the FEP popu-
lation is particularly important.
The few published studies seeking biomarker evidence of comple-
ment activation and dysregulation in adultswith schizophrenia are con-
fusing and contradictory (Mayilyan et al., 2008; Hakobyan et al., 2005;
Wong et al., 1996). As a ﬁrst step towards clariﬁcation,wemeasured se-
lected complement markers in serum from FEP and controls in samples
from the PUMP and GAP studies. Prior to consideration of independent-
ly contributing variables, one complement marker emerged as signiﬁ-
cantly different between the groups. TCC, a marker of terminal
pathway activation, was signiﬁcantly lower in serum of FEP patients
compared to controls. Measured TCC values in all samples were higher
than expected, in part because only archived serum sampleswere avail-
able – complement activation markers are best measured in freshly ob-
tained EDTA plasma to minimise artefactual ex vivo activation. The keyrkers in ﬁrst episodepsychosis, Schizophr. Res. (2017), https://doi.org/
6 M. Kopczynska et al. / Schizophrenia Research xxx (2017) xxx–xxxcontributing independent variables considered were age, sex, ethnicity,
tobacco and cannabis smoking. A signiﬁcant impact of tobacco smoking
on biomarker measurements was previously described in other studies
(Kew et al., 1985; Robbins et al., 1991); smoking has been shown to
cause complement activation and induce an acute phase response likely
to impact levels of complement proteins (Kobayashi et al., 1988; Sunyer
et al., 2009). A recent meta-analysis also established that daily tobacco
use is associatedwith an increased risk of psychotic disorder and an ear-
lier age at onset of psychotic illness (Gurillo et al., 2015). A notable inter-
dependence was seen between TCC levels and tobacco smoking; TCC
levels were lower both in FEP cases and smokers and the signiﬁcance
of TCC for differentiating cases and controls was lost when smoking
was corrected for.
Themultivariatemodels showed interdependence between comple-
ment analytes and demographic and lifestyle variables. The chosen
model (Model B) revealed, after stepwise selection, two complement
proteins, C3 and C4, as signiﬁcantly different between the FEP and con-
trol groups, with four complement analytes (C5, TCC, C1 inhibitor and
FHR125) trending towards signiﬁcance and strengthening the model.
ROC analysis demonstrated a predictive value (AUC) for the model of
0.79 for distinguishing FEP from controls, considered “moderately pre-
dictive” (Greiner et al., 2000). Complement analytes alone or demo-
graphics (sex, age, ethnicity) contributed to similar degrees to the
predictive value (AUC 0.63 and 0.69 respectively). It is notable that
the complement analytes selected in themodel have roles in the classi-
cal pathway. C4 is an essential classical pathway component, implicated
by genetic and expression studies in the pathology of schizophrenia, C3
is the key complement protein essential for efﬁcient opsonisation
regardless of the initiating pathway; while C1inh is the sole plasma reg-
ulator of classical pathway activation. The ﬁndings therefore support a
role for classical pathway dysregulation in the early stages of develop-
ment of schizophrenia. Interestingly, C3 and C4 levels are also associat-
ed with metabolic syndrome development, which is commonly
associated with established psychosis (Liu et al., 2016). Despite the
described complement dysregulation suggesting inﬂammatory compo-
nent in FEP pathogenesis, there is no signiﬁcant alteration of CRP. The
disconnection between inﬂammation and CRP levels is not without pre-
cedent and has been reported in several other inﬂammatory conditions,
including SLE (Gaitonde et al., 2008).
The current data set has several limitations: the sample size is small,
the patient group heterogeneous and biased in terms of sex and ethnic-
ity. The serum samples available for testing are not ideal for measure-
ment of complement analytes which are prone to ex vivo artefact. A
further limitation is the fact that the majority of the patients were not
drug naïve at the time of blood sample collection and details of drug
therapy were not available. There is a possibility that antipsychotic
treatment drives some of these differences, as described for cytokines
in the past (Baumeister et al., 2016). In our study, we cannot control en-
tirely for the effect of each drug individually. The immediate previous
history of infectious illness or anti-inﬂammatory drug history was also
not available for the analysis. Groupsmore representative of the general
population (matched for condition, but also smoking habit and ethnici-
ty) would help to reduce the number of incorrectly classiﬁed cases, in
particular the number of false positives.
Our ﬁndings suggest that measurement of selected complement
analytes interrogating the classical pathway could contribute to the
early diagnosis of psychosis. A large study, planned prospectively,
minimising sample bias and using appropriately collected and stored
EDTA plasma samples, is needed to conﬁrm and extend the ﬁndings. It
is also important to explore complement biomarkers in individuals con-
sidered at high risk of developing schizophrenia and patients with
established schizophrenia to discover whether complement dysregula-
tion is a feature of very early disease and if it is maintained in later
disease stages.
Supplementary data to this article can be found online at https://doi.
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